cas 40794-04-5|| where to buy 4-Chloro-2-methoxy-1-methylbenzene

Название продукции:4-Chloro-2-methoxy-1-methylbenzene

IUPAC Name:4-chloro-2-methoxy-1-methylbenzene

Упаковочная единица	Доступно для заказа	Цена ($)
CM283380-5g	in stock	ǑǑ
CM283380-10g	in stock	ŪȖǫ
CM283380-25g	in stock	Ūƿȯ
CM283380-100g	in stock	ǑŪƛ

Только для использования в НИОКР..

Форма запроса

Химическое название

Номер CAS

Количество*

Необходимые спецификации*
(% пробы, категория материала и т.д.)

Контактное лицо*

Электронная почта*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 40794-04-5 regularly via the above email.

Дополнительные примечания

Verification code*

refresh

: Номер CAS:40794-04-5; Молекулярная формула:C8H9ClO; Точка плавления:-; Smiles-код:CC1=CC=C(Cl)C=C1OC; Плотность:

: Номер в каталоге:CM283380; Молекулярная масса:156.61; Точка кипения:204°C at 760 mmHg; Номер Mdl:MFCD07368289; Хранение:Store at 2-8°C.

: Crinecerfont; The New England Journal of Medicine publishes the primary CAHtalyst™ Adult Phase 3 study results of Crinecerfont for the treatment of congenital adrenal hyperplasia (CAH). Classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21OHD) is a rare genetic disorder, affected by a lack of cortisol and/or aldosterone. Corticotropin-releasing factor type 1 receptor (CRF1) antagonism is shown to clinically decrease ACTH production and adrenal androgen levels.
Neurocrine's Crinecerfont is an investigational, selective CRF1 antagonist being developed to reduce and control excess adrenocorticotropic hormone (ACTH) and adrenal androgens. The phase 3 study meets primary and important key secondary endpoints, including a significant reduction in androstenedione levels and lowering glucocorticoid dosing.